甲真菌病临床评分指数指导伊曲康唑和特比萘芬治疗甲真菌病的疗效对比研究  

Therapeutic Effects of Itraconazole and Terbinafine for the Treatment of Onychomycosis Evaluated with Scoring Clinical Index

作　　者：胡燕[1] 杨莉佳[1] 戴迅毅[1] 张海平[1] 魏聆[1] 华海康[1] 戚稼[1] 孙慧[1] 郑渊[1] 蒋屏东[1] 

机构地区：[1]南京医科大学附属无锡市第二人民医院皮肤科,无锡214002

出　　处：《中华皮肤科杂志》2005年第8期470-473,共4页Chinese Journal of Dermatology

摘　　要：目的评价甲真菌病临床评分指数(SCIO)指导伊曲康唑冲击和特比萘芬连续疗法治疗甲真菌病的疗效、安全性及费用疗效比。方法制定SCIO评分体系,对200例甲真菌病患者的靶甲进行SCIO评分,根据SCIO积分范围随机分为2组,分别给予伊曲康唑冲击治疗和特比萘芬连续治疗。结果2种药物均有较好的抗真菌疗效。伊曲康唑组和特比萘芬组近、中、远期临床和真菌学疗效差异均无统计学意义(P>0.05),伊曲康唑组远期复发率4.26%,特比萘芬组尚未观察到复发病例。伊曲康唑组不良事件发生率为23%,特比萘芬组为21%(P>0.05)。Ⅱ度患者伊曲康唑组费用疗效比低于特比萘芬组,Ⅲ度和Ⅳ度患者特比萘芬组费用疗效比低于伊曲康唑组,但差异均无统计学意义(P>0.05)。结论SCIO具有一定的科学性和实用性,指导伊曲康唑冲击和特比萘芬连续疗法治疗甲真菌病显示同样有效且安全。Objective To assess the efficacy, safety and cost-effectiveness of itraconazole and terbinafine for the treatment of onychomycosis, evaluated by the scoring clinical index of onychomycosis （SCIO）. Methods The system of SCIO was established and applied to evaluate 200 patients with onychomyeosis, whn were randomly divided into two treatment groups, one with intermittent pulse itraeonazole （Group Ⅰ） and continuous terdinafine （Group T）. The therapeutic responses were assessed based on the scores of the target nails with SCIO system. Results Good antifungal effects were aehieved in both groups. The shortmedium-, and long-term clinical and mycological cure rates were not significantly different in the two groups （P 〉 0.05）. The long-term recurrence rates were 4.26% in Group Ⅰ, and 0 in Group T. Adverse reactions were observed in 23% of Group Ⅰ , and 21% in Group T （P 〉 0.05）. Treatment with itraconazole seemed more cost-effeetive in degree Ⅱ patients, and less cost-effective in degree Ⅲ and Ⅳ patients, than that with terbinafine, however, the differences were not statistically significant （P 〉 0.05）. Conclusions The SCIO system is practical to assess the therapeutie effects of itraconazole and terbinafine for patients with onychomycosis. Treatment of onychomycosis with the two drugs is equally effective and safe.

关 键 词：甲癣 伊曲康唑 特比荼芬 临床评分指数 疗效对比研究 特比萘芬 甲真菌病 连续治疗 评分指数 临床 

分 类 号：R756[医药卫生—皮肤病学与性病学]